Aleve PM Enters Nighttime Pain-Relief Market After 160-Count Label Approved
This article was originally published in The Tan Sheet
Executive Summary
Bayer HealthCare business on Sept. 15 announced the product with 220mg naproxen sodium and 25mg diphenhydramine HCL is available at U.S. retailers. Its NDA was approved in January, but Bayer waited for FDA’s OK on 160-count labeling before launching the product.
You may also be interested in...
Apotex' Aleve PM Rival Could Have 180-Day Exclusivity As A CGT
US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), the FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.
Latest Aleve PM Copy Could Have 180-Day Exclusivity From More Competition
US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”